IRIS
MAZZASCHI, GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.306
EU - Europa 2.206
AS - Asia 1.522
SA - Sud America 254
AF - Africa 134
OC - Oceania 9
Totale 6.431
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.251
IT - Italia 704
SG - Singapore 562
CN - Cina 435
IE - Irlanda 326
HK - Hong Kong 276
SE - Svezia 275
DE - Germania 261
BR - Brasile 235
NL - Olanda 126
FR - Francia 106
ZA - Sudafrica 98
AT - Austria 76
FI - Finlandia 75
IN - India 69
GB - Regno Unito 68
RU - Federazione Russa 60
BD - Bangladesh 41
CA - Canada 30
CZ - Repubblica Ceca 28
BE - Belgio 27
CI - Costa d'Avorio 27
TR - Turchia 25
KR - Corea 19
MX - Messico 17
ES - Italia 16
VN - Vietnam 15
ID - Indonesia 12
PL - Polonia 11
UA - Ucraina 11
AR - Argentina 10
PK - Pakistan 10
IQ - Iraq 9
IR - Iran 9
AU - Australia 8
LU - Lussemburgo 8
JP - Giappone 7
LT - Lituania 7
UZ - Uzbekistan 6
MA - Marocco 5
AZ - Azerbaigian 4
EE - Estonia 4
IL - Israele 4
TH - Thailandia 4
CH - Svizzera 3
DK - Danimarca 3
TT - Trinidad e Tobago 3
BG - Bulgaria 2
CO - Colombia 2
EC - Ecuador 2
JO - Giordania 2
KG - Kirghizistan 2
MD - Moldavia 2
NO - Norvegia 2
PS - Palestinian Territory 2
SA - Arabia Saudita 2
TN - Tunisia 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
BB - Barbados 1
BO - Bolivia 1
BY - Bielorussia 1
CL - Cile 1
DO - Repubblica Dominicana 1
EG - Egitto 1
HN - Honduras 1
HU - Ungheria 1
JM - Giamaica 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
MK - Macedonia 1
MT - Malta 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
PH - Filippine 1
QA - Qatar 1
RS - Serbia 1
TW - Taiwan 1
Totale 6.431
Salva come PNG Salva come JPEG
Città #
Ashburn 410
Singapore 396
Dublin 323
Chandler 313
Hong Kong 269
Santa Clara 253
Parma 175
Beijing 135
Boardman 133
Munich 127
Ann Arbor 126
Johannesburg 98
Shanghai 97
New York 69
Bologna 64
Vienna 57
Milan 46
Bremen 41
Helsinki 39
Princeton 38
Columbus 34
Los Angeles 34
Moscow 33
Dearborn 31
Marseille 31
Nuremberg 28
Abidjan 27
Frankfurt am Main 26
Turku 26
Brussels 25
Hefei 25
Nanjing 24
Dallas 23
Rome 23
West Jordan 22
Verona 21
Bengaluru 19
Modena 19
São Paulo 19
Chicago 18
Des Moines 18
Brno 15
Rio Saliceto 15
Seoul 15
The Dalles 15
Wilmington 15
London 13
Pune 13
Toronto 12
Boston 11
Brooklyn 11
Fremont 11
Guangzhou 11
Jinan 11
Amsterdam 10
Düsseldorf 10
Izmir 10
Montreal 10
Seattle 10
Torrile 10
Atlanta 9
Chongqing 9
Jakarta 9
Olomouc 9
Sorbolo 9
Trento 9
Ardea 8
Falls Church 8
Ho Chi Minh City 8
Nanchang 8
Reggio Emilia 8
San Mateo 8
Florence 7
Guarulhos 7
Hangzhou 7
Houston 7
Belo Horizonte 6
Curitiba 6
Kocaeli 6
Manchester 6
Mexico City 6
North Bergen 6
Portsmouth 6
Rio de Janeiro 6
Stockholm 6
Venice 6
Bolzano 5
Brescia 5
Hebei 5
Jiaxing 5
Kunming 5
Lauterbourg 5
Malo 5
Melbourne 5
Naples 5
Norwalk 5
Redwood City 5
Salvador 5
San Francisco 5
Tashkent 5
Totale 4.223
Salva come PNG Salva come JPEG
Nome #
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients 146
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 144
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 143
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 135
Imatinib mesylate-induced cardiomyopathy involves resident cardiac progenitors 128
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 126
Low PD-1 expression in Cytotoxic CD8+ Tumor infiltrating Lymphocytes Confers an Immune Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value 123
INTEGRATION OF TISSUE PD-1/PD-L1 IMMUNE CHECKPOINT WITH COMPUTED TOMOGRAPHY (CT) BASED TEXTURE ANALYSIS EXHIBITS HIGH PROGNOSTIC IMPACE ON SURGICALLY RESECTED NON SMALL CELL LUNG CANCER (NSCLC) 118
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 114
Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancer 111
BLOOD AND LYMPHATIC VESSELS CONSTITUTE AN ESSENTIAL COMPONENT OF THE IMMUNE MICROENVIRONMENT AND ITS IMPACT ON NON SMALL CELL LUNG CANCER (NSCLC) CLINICAL OUTCOME 110
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 103
Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis 103
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 100
227P Sexual dimorphism in immune profile of early and advanced NSCLC 99
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 99
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 98
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 97
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC 97
Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer 96
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 94
SURGICAL SAMPLING IS AN EMERGING ISSUE IN THE ASSESSMENT OF THE IMMUNE CONTEXTURE IN NON SMALL CELL LUNG CANCER (NSCLC) 93
Favorable clinical outcome and response to immunotherapy share a common PD-L1/PD-1 based NSCLC immune contexture 90
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 89
IMPACT OF THE TISSUE DISTRIBUTION OF SUBPOPULATIONS OF TILS AND PD-L1 EXPRESSION ON THE CLINICAL OUTCOME OF NSCLC 88
Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer 88
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 86
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 86
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 84
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 84
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 83
91 Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors 82
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma 82
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 81
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 80
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 77
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 77
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 77
THE ROLE OF BLOOD CHOLESTEROL QUALITY IN PATIENTS WITH ADVANCED CANCER RECEIVING IMMUNE CHECKPOINT INHIBITORS 73
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 71
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status 70
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 67
Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma 65
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non–Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors 64
Differentially regulated high-throughput CT imaging features correlate to distinct tumor immune contextures portraying a radiomic signature with prognostic impact on surgically resected NSCLC 64
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 63
Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis 63
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario 60
The role of c-met as a biomarker and player in innate and acquired resistance in non-small-cell lung cancer: Two new mutations warrant further studies 60
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study 60
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology 60
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score 59
Unraveling the link between cholesterol and immune system in cancer: From biological mechanistic insights to clinical evidence. A narrative review 54
The radiological appearances of lung cancer treated with immunotherapy: a review 53
Evaluation of PBRM1, PD-L1, CD31, and CD4/CD8 ratio as a predictive signature of response to VEGFR-TKI–based therapy in patients with metastatic renal cell carcinoma (mRCC) with IMDC intermediate prognosis: Results from the APAChE-I Study 53
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 53
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 53
Deciphering the different patterns of acquired resistance in immunotherapy treated NSCLC patients through an integrated clinical and blood immuneinflammatory profiling 52
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 52
Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer 52
Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC 50
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 49
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 49
Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature 48
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors 47
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy 47
Advanced CT imaging features reflect distinct tissue immune profiles and exhibit high prognostic impact on NSCLC 47
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients 47
1599P Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study 46
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 45
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis 45
Drug-drug interactions (DDIs) in elderly patients with metastatic renal cell carcinoma (mRCC) treated with cabozantinib within the multicenter prospective trial ZEBRA/Meet-URO 9 43
9P Identification of a μCT-based radiomic signature of CD8+ tumour infiltrating lymphocytes in an orthotopic murine model 43
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review 42
Burnout and Oncology: an irreparable paradigm or a manageable condition? Prevention strategies to reduce Burnout in Oncology Health Care Professionals 41
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 41
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 40
A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study 40
Integration of tissue and circulating parameters identifies a favorable immune profile in NSCLC patients treated with nivolumab 40
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer 39
EP.15B.05 Predictors of 30-Day Mortality after Systemic Therapy in Hospitalized Lung Cancer Patients: A Retrospective Single-Center Observational Study 38
What Is the Real Impact of Concomitant Antibiotics or Proton Pump Inhibitors on Efficacy of Atezolizumab-Based Regimens in Patients With NSCLC? 36
The distinct prognostic impact of circulating lipid profile according to neutrophil to lymphocyte ratio in patients with advanced solid tumors treated with immune check point inhibitors. 36
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study 36
Abscopal effect as part of treatment of oligometastatic head and neck cancer: A case report 35
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations 35
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations 35
Evaluation of PBRM1, PD-L1, CD31 and CD4/CD8 ratio as predictive biomarkers of response to VEGFR-TKI-based therapy in metastatic renal cell carcinoma (mRCC) patients with IMDC intermediate prognosis: Results from the APAChE-I study 33
Immune checkpoint inhibitors in hepatocellular cancer patient with congenital haemophilia A 32
Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma 32
The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab 30
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences 28
Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative review 27
Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups 27
Identification of a radio-immune signature with high prognostic value in surgically resected NSCLC 26
Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC 26
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 26
Non-homogenous intratumor ionizing radiation doses synergize with PD1 and CXCR2 blockade 20
MET alterations as resistance mechanisms of dabrafenib-trametinib in BRAF p.V600E mutated non-small cell lung cancer patient 7
Totale 6.586
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.794
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.794
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021241 0 11 10 23 33 33 16 18 24 17 35 21
2021/2022272 13 13 15 19 5 12 60 10 6 10 21 88
2022/20231.306 121 129 72 109 143 143 38 73 391 7 56 24
2023/2024876 33 60 28 36 110 157 97 36 62 80 49 128
2024/20252.804 92 177 226 197 261 244 183 132 253 271 237 531
2025/2026700 582 118 0 0 0 0 0 0 0 0 0 0
Totale 6.586